| ML-228 |
KC7F2 |
1357171-62-0 |
| 3-(1-methyl-1H-pyrazol-3-yl)propiolic acid |
1354706-29-8 |
1354706-29-8 |
| (S)-2-amino-2,4-dimethylpentan-1-ol |
[1352447-28-9 |
1352447-28-9 |
| N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide |
化合物GSK503 |
1346572-63-1 |
| CEP-33779 |
N-[3-(4-甲基-1-哌嗪基)苯基]-8-[4-(甲磺酰基)苯基]-[1,2,4]三唑并[1,5-A]吡啶-2-胺 |
1346168-57-7 |
| EIPA hydrochloride |
EIPA HYDROCHLORIDE |
1345839-28-2 |
| 3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide |
1346233-68-8 |
1346233-68-8 |
| GSK 2330672 |
GSK 2330672 |
1345982-69-5 |
| Citarinostat |
西他司他 |
1316215-12-9 |
| VU 591 hydrochloride |
VU 591 HYDROCHLORIDE |
1315380-70-1 |
| Teijin compound 1 |
化合物 T19230 |
1313730-14-1 |
| 3,4-Dihydroxy-9,10-dioxo-N-(4-(trifluoroMethyl)phenyl)-9,10-dihydroanthracene-2-sulfonaMide |
3,4-Dihydroxy-9,10-dioxo-N-(4-(trifluoroMethyl)phenyl)-9,10-dihydroanthracene-2-sulfonaMide |
1313738-90-7 |
| Target Protein-binding moiety 4 |
1300019-38-8 |
1300019-38-8 |
| 3-Bromo-7H-furo[3,4-b]pyridin-5-one |
3-溴-七氢-呋喃并[3,4-B]吡啶-5-酮 |
1303968-43-5 |
| (S)-2-((2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide |
GDC0326 |
1282514-88-8 |
| PF-4989216 |
4-(4-氰基-2-氟苯基)-2-吗啉-5-(1H-1,2,4-三唑-5-基)噻吩-3-腈 |
1276553-09-3 |
| NMS-P118 |
2-[1-(4,4-二氟环己基)-4-哌啶基]-6-氟-2,3-二氢-3-氧代-1H-异吲哚-4-甲酰胺 |
1262417-51-5 |
| G1T28 |
曲拉西利双盐酸盐 |
1977495-97-8 |
| PF-CBP-1.HCl |
化合物PF-CBP1 |
1962928-21-7 |
| OABK (hydrochloride) |
1984862-48-7 |
1984862-48-7 |
